Nyxoah SA (NYXH)

Market Cap	122.23M -71.0%
Revenue (ttm)	11.76M +121.6%
Net Income	-105.77M
EPS	-2.78
Shares Out	43.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	164,324
Open	3.000
Previous Close	3.090
Day's Range	2.770 - 3.000
52-Week Range	2.770 - 8.800
Beta	0.62
Analysts	Strong Buy
Price Target	11.25 (+298.94%)
Earnings Date	Mar 19, 2026

About NYXH

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 2, 2021
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: NYXH
• Website: https://www.nyxoah.com

Financial Performance

In 2025, Nyxoah's revenue was 10.02 million, an increase of 121.63% compared to the previous year's 4.52 million. Losses were -90.09 million, 52.1% more than in 2024.

Financial numbers in EUR

Analyst Summary

According to 4 analysts, the average rating for NYXH stock is "Strong Buy." The 12-month stock price target is $11.25, which is an increase of 298.94% from the latest price.

Price Target

$11.25

(298.94% upside)

Analyst Consensus: Strong Buy